Heparinex/Choncept sign deals with India's Biological E Limited

Texas, USA-based biotechnology firms Heparinex and Choncept, part of life science venture fund Emergent Technologies, have established deals with Indian biopharmaceutical firm Biological E Limited that provide the latter with options to selected candidate heparin and chondroitin-based compounds.

The agreements are designed to combine the core strengths of Heparinex and Choncept, which are, respectively, the synthesis of recombinant anticoagulants and the production of chondroitin via bacterial fermentation, with BE's development programs. The initial focus of the project, financial terms of which were not revealed, will be an assessment of the licensed compounds in the nutraceutical, orthopedic and drug discovery fields, including the $4.0 billion anticoagulant segment.